Research & Education
CURE Expert Connections
Email Sign Up
To start your customized experience click the start button
Customize your homepage by selecting specific cancer types.
Cancer of Unknown Primary
Diet and Exercise
Gastrointestinal stromal tumor
General Financial Topics
General Psychosocial Aspect Topics
Head & Neck Cancer
Mantle Cell Lymphoma
Metastatic Breast Cancer
Side Effect Management
Small Lymphocytic Lymphoma (SLL)
Advocacy & Research
Share Your Story
Newsletter Sign Up
Ovarian Cancer Heroes
Bone Health Champions
Terms & Conditions
Cure Media Group, LLC.
2 Clarke Drive
Cranbury, NJ 08512
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
With Addition of Checkpoint Inhibitors, Chemotherapy 'Not Going Away Anytime Soon'
With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.
Tumor Mutation Burden May Be Predictive of Depression in Patients With Lung Cancer
Dr. Daniel McFarland
Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.
Tumor Mutation Burden May Identify Those at Risk for Depression
Kristie L. Kahl
Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.
Immuno-Oncology Initiative Seeks to Overcome Implementation Challenges
The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.
Immunotherapy Side Effects Could Mean Treatment Is Working in Non-Small Cell Lung Cancer
Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.
Gender Does Not Influence Immunotherapy Response
Recent study findings show no significant difference in treatment efficacy or overall survival between men and women.
Immunotherapy in NSCLC: Looking Toward the Future
Dr. Jyoti Patel and patient Laura O’Brien share their parting perspectives on stage III non-small cell lung cancer and the future of treatment.
A Team Effort in NSCLC: Support and Information
The value of support and credible information is emphasized regarding one’s journey through non-small cell lung cancer.
Receiving Immunotherapy for Stage III NSCLC
Together with Dr. Jyoti Patel, Laura O’Brien shares insight on her experience of receiving immunotherapy for stage III non-small cell lung cancer.
Stage III NSCLC: Enrolling on a Clinical Trial
Laura O’Brien elucidates her experience of enrolling on a clinical trial following her diagnosis of stage III non-small cell lung cancer.
Not a member?
Sign up now!
Continue without login
OPTIONAL INFORMATION: The following information helps us tailor CURE to fit your needs
Please type below what best describes your interests and click on the selection(s):
I am a:
Please list other: